Sign in
Taking people in United StatesPhase 2

Injections of AGN-151607-DP for hand and arm tremor called essential tremor

Tests AGN-151607-DP injections against placebo in adults with upper limb essential tremor.

Key facts

Who runs it
AbbVie
Where
Amherst, Boca Raton, Carlsbad, Charlottesville, Commack, Dallas, Fresno, Frisco, Fullerton, Greenfield, Houston, Memphis, New Albany, Orlando, Overland Park, Pensacola, Spokane, Stamford, and Winston-Salem, United StatesSee the 19 sitesAlso in 1 other country, 2 sites
Trial code
Registry title
Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Essential Tremor
Status
Recruiting
Phase
Phase 2
People taking part
94 people, planned
Started
23 Jun 2026
Expected to end
Nov 2028
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • AGN-151607-DP
  • Placebo for AGN-151607-DP
Record updated
27 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with essential tremor of the arms and hands. It tests AGN-151607-DP injections into the muscle against a placebo (dummy treatment).

Age
18 Years to 85 Years
Sex
All sexes can join
Disease stage
Essential tremor diagnosed by the modified TRIG criteria. The shaking happens in both hands and forearms when holding a position, with or without shaking during movement. The person says the tremor is constant, even if its strength changes.

Main reasons for not taking part

  • Body weight under 50 kg (110 pounds) at screening
  • Muscle or nerve diseases that raise the risk from botulinum toxin, such as muscular dystrophy, myasthenia gravis, Eaton-Lambert syndrome or ALS
  • Mitochondrial disease or another serious disease affecting the link between nerves and muscles
  • Allergy or strong sensitivity to AGN-151607-DP, its ingredients or other botulinum toxins

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Minimum body weight of 50 kg (110 pounds) at Screening
  • Diagnosis of essential tremor (ET) in accordance with the modified Tremor Research Investigation Group (TRIG) criteria, as follows:; Bilateral postural tremor with or without kinetic tremor, involving hands and forearms; Tremor of other body parts may or may not be present in addition to upper limb (UL) tremor; Bilateral tremor may or may not be asymmetric; Tremor that is reported by the participant to be persistent, although the amplitude may fluctuate

Who cannot take part

  • History of any medical condition that may put the participant at increased risk with exposure to purified botulinum toxin type A complex, including diagnosed muscular dystrophy (e.g., Duchenne's muscular dystrophy), myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, mitochondrial disease, or any other significant disease that might interfere with neuromuscular junctional disorders
  • History of an allergic reaction to or significant sensitivity to AGN-151607-DP or its excipients and/or other botulinum toxins

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 85 years old?

Where in United States

Also in 1 other country, 2 sites

  • Dent Neurologic Institute - Amherst /ID# 277242Amherst, United StatesTaking people
  • Parkinson'S Disease & Movement Disorders Center Of Boca Raton /ID# 277079Boca Raton, United StatesTaking people
  • The Neurology Center of Southern California - Carlsbad /ID# 278194Carlsbad, United StatesTaking people
  • University of Virginia /ID# 278191Charlottesville, United StatesTaking people
  • True North Neurology /ID# 278118Commack, United StatesTaking people
  • Texas Neurology /ID# 277067Dallas, United StatesTaking people
  • Neuro Pain Research Center /ID# 277899Fresno, United StatesTaking people
  • Lone Star Neurology /ID# 278266Frisco, United StatesTaking people
  • Neurology Center Of North Orange County /ID# 278490Fullerton, United StatesTaking people
  • Center For Neurological Disorders /ID# 277048Greenfield, United StatesTaking people
  • Houston Methodist Hospital /ID# 277326Houston, United StatesTaking people
  • Veracity Neuroscience /ID# 277081Memphis, United StatesTaking people
  • Mount Carmel Health System /ID# 278234New Albany, United StatesTaking people
  • Charter Research - Winter Park /ID# 277875Orlando, United StatesTaking people
  • Kansas Institute of Research /ID# 277068Overland Park, United StatesTaking people
  • Emerald Coast Neurology /ID# 277898Pensacola, United StatesTaking people
  • Inland Northwest Research /ID# 277077Spokane, United StatesTaking people
  • New England Institute for Clinical Research /ID# 277315Stamford, United StatesTaking people
  • Neurology - Triad /ID# 277088Winston-Salem, United StatesTaking people

About the trial

What the trial wants to find out

Upper limb essential tremor (UL ET) is a movement disorder characterized by postural and/or kinetic tremor. It can cause difficulty with everyday tasks such as writing, pouring, and eating. This study will assess if AGN-151607-DP is safe and effective by assessing adverse events and change in disease activity in adult participants with UL ET.

Read full original descriptionShow less

AGN-151607-DP is an investigational drug being developed to treat UL ET. Participants will be randomly placed in treatment groups to receive either AGN151607-DP or matching placebo. Approximately 94 adult participants with upper limb essential tremor will be enrolled in approximately 40 sites in the United States/Canada.

Participants will receive intramuscular injections of AGN-151607-DP or matching placebo. Duration of the study is approximately 72 weeks.

The effect of the treatment will be checked by completion of questionnaires and side effects will be monitored by medical assessments.

The 2 groups in the trial

  • AGN-151607-DPTreatment being tested

    Participants will receive AGN-151607-DP.

  • Placebo for AGN-151607-DPPlacebo, for comparison

    Participants will receive Placebo for AGN-151607-DP.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Phase 2b Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period to Evaluate the Efficacy and Safety of AGN-151607-DP (USAN: gemibotulinumtoxinA) for the Treatment of Upper Limb Essential Tremor in Adults
Plain-language title
Injections of AGN-151607-DP for hand and arm tremor called essential tremorGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT07673107, who can take part
Record updated
27 October 2026